By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem announced after the close of the market on Monday that revenues during its fiscal first quarter rose a fraction of 1 percent and that it is developing two molecular diagnostic platforms as part of a strategy to move to "higher value products and systems directed at the non-academic market segment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.